pocketful logo
Concord Biotech Ltd logo

Concord Biotech Ltd

NSE: CONCORDBIO BSE: 543960

₹1092.30

(-0.79%)

Tue, 24 Mar 2026, 02:19 am

mtf coin illustrationMTF 5x

Company History

1984

  • The Company was originally incorporated as Servomed Pharmaceuticals Private Limited.

1985

  • The Company's name was changed to Concord Pharmaceuticals Private Limited.

1986

  • The Company was deemed to have become a public company pursuant to Section 43A of Companies Act, 1956.

2000

  • The Company was acquired by Mr. Sudhir Vaid, one of the Promoters.

2001

  • The Company was renamed to Concord Biotech Limited.
  • The Company became a public company from a deemed public company and a fresh certificate of incorporation was issued by the RoC.

2002

  • The Company expanded its production capacity of enzymes.

2003

  • The Company's facility at Dholka was certified for commissioning and commencement of production of various enzymes by technical consultants.

2004

  • The Company received an investment from Rakesh Jhunjhunwala and Rekha Jhunjhunwala.

2005

  • The Company underwent its first USFDA inspection and the API facility was classified as acceptable.

2008

  • The Company underwent its second USFDA inspection and the API facility was classified as acceptable.

2010

  • The Company received a drug master file registration certificate for tacrolimus hydrate from the Pharmaceuticals and Medical Devices Agency, Japan.

2011

  • The Company underwent its first EU GMP inspection of the manufacturing facility by the Government of Upper Bavaria-Central Medicines Control Bavaria (GMP/GCP).
  • The Company initiated CRAMs services in areas of new chemical entity (NCE) or Generic APIs.
  • The Company received a drug master file registration certificate for tacrolimus hydrate from the Pharmaceuticals and Medical Devices Agency, Japan.

2012

  • The Company received an original drug substance registration certificate for mycophenolate mofetil from the Pharmaceuticals and Medical Devices Agency, Japan.

2013

  • The Company underwent its third USFDA inspection and the API facility was classified as acceptable.

2014

  • The Company received a certificate of drug substance registry for Ciclosporin JP from the Pharmaceuticals and Medical Devices Agency, Japan.

2015

  • The Company underwent its fourth USFDA inspection of the Dholka facility and the inspection was concluded as 'closed'.
  • The Company underwent its second EU GMP inspection of the manufacturing facility.
  • The Company received an accreditation certificate of foreign drug manufacturing for non-sterile drugs from the Minister of Health, Labour and Welfare of Japan.

2016

  • The Company established a facility at Valthera, Gujarat.
  • The Company's in-house R&D facility located at Valthera was recognized by the Ministry of Science and Technology, Government of India.
  • The Company received an investment from Helix Investment Holdings Pte. Limited.

2017

  • The Company underwent its first USFDA inspection at the Valthera facility and received an establishment inspection report.

2018

  • The Company underwent its fifth USFDA inspection and received a 'no action indicated' classification for the facility located at Dholka.
  • The Company received a GMP certification from the Food and Drugs Control Administration for the Valthera and Dholka units.
  • The Company underwent its second USFDA inspection at the Valthera facility and received an establishment inspection report.
  • The Company established a Joint Venture in Japan.

2019

  • The Company received two ANDA approvals.
  • The Company expanded its business in the critical care segment in India.
  • The Company commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg.

2020

  • The Board permitted the layout plan for the proposed injectable manufacturing unit at the Valthera facility.
  • The Company received two ANDA approvals.
  • The Company made its first shipment of Mycophenolate Sodium Tablets to the US market.

2021

  • The Company commenced operations at the second API facility at Limbasi.
  • The Company underwent its third EU GMP inspection of the manufacturing facility located in Dholka.

2023

  • The Company completed the USFDA inspection at the Limbasi facility.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800